[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648801":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":40,"collaborators":11,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":11,"enrollmentInfo":51,"targetDuration":11,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ALS patients with anti-NRIP autoantibody","EXPERIMENTAL",null,[13],"Device: plasmapheresis",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DEVICE","plasmapheresis","Using plasmapheresis to remove plasma anti-NRIP autoantibody; each patient receive 3 courses of plasmapheresis with 3 months apart",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Li-Kai Tsai, MD, PhD","CONTACT","+886972651560","milikai@ntuh.gov.tw",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":11,"geoPoint":11,"contacts":34},"RECRUITING","Taipei City","Taipei","100","Taiwan","TW",[35,37,38],{"name":22,"role":23,"phone":36,"phoneExt":11,"email":25},"886-2-972651560",{"name":11,"role":23,"phone":11,"phoneExt":11,"email":25},{"name":22,"role":39,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"type":41,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100648801","plasmapheresis-in-amyotrophic-lateral-sclerosis-with-autoantibody-against-nrip-2-paladin2-100648801",false,"NCT07726563","Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP 2 (PALADIN2)","PALADIN2","Inclusion Criteria:\n\n* ALS patients above 20-year-old who have anti-NRIP autoantibody in plasma\n* Agree to receive plasmapheresis treatment\n* Agree to participate in the study and receive serial examinations\n\nExclusion Criteria:\n\n* Under permanent ventilator support\n* Cannot receive plasmapheresis treatment or serial examinations\n* Under pregnancy\n* Blood fibrinogen level below 50 mg\u002Fdl\n* Belong to special subtype of ALS, such as primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, flail leg syndrome.","ALL","20 Years",{"count":52,"type":53},20,"ESTIMATED","INTERVENTIONAL",[56],"NA","10-20% of patients with ALS have anti-NRIP autoantibody and the titer of anti-NRIP autoantibody is correlated with motor functional decline and mortality in ALS. The PALADIN2 clinical trial is a single arm study, which intends to enroll 20 ALS patients having anti-NRIP autoantibody in plasma. Patients will receive 3 courses of plasmapheresis per 3 months in order to maintain low concentration of anti-NRIP autoantibody in plasma. The study will follow up these patients for another 6 months after plasmapheresis. This project will potentially confirm the efficacy and safety of plasmapheresis for ALS patients having anti-NRIP autoantibody.",[59,60,61],"Amyotrophic Lateral Sclerosis (ALS)","Autoantibody","Plasmapheresis",[63,64,17],"amyotrophic lateral sclerosis","anti-NRIP autoantibody","2026-07-21",{"date":67,"type":68},"2026-07-24","ACTUAL",{"date":70,"type":68},"2026-05-19",{"date":72,"type":53},"2029-07-31",{"name":5,"class":6},1]